The pathophysiology of polycystic liver disease
Polycystic liver disease (PLD) is a rare genetic disorder characterized by ≥10 cysts within the liver parenchyma. PLD occurs independently as autosomal dominant polycystic liver disease (ADPLD) or as extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Although most patients with PLD are asymptomatic, a subset of patients will develop severe hepatomegaly affecting quality of life.1 (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2024 Category: Gastroenterology Authors: Ren ée Duijzer, Melissa M. Boerrigter, Tom J.G. Gevers, Joost P.H. Drenth Tags: Hepatology Snapshot Source Type: research
B cell characteristics define HCV reinfection outcome
In individuals highly exposed to hepatitis C virus (HCV), reinfection is common, suggesting that natural development of sterilising immunity is difficult. In those that are reinfected, some will develop a persistent infection, while a small proportion repeatedly clear the virus, suggesting natural protection is possible. The aim of this study was to characterise immune responses associated with rapid natural clearance of HCV reinfection. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2024 Category: Gastroenterology Authors: Alexander P. Underwood, Money Gupta, Bing-Ru Wu, Auda A. Eltahla, Irene Boo, Jing Jing Wang, David Agapiou, Arunasingam Abayasingam, Arnold Reynaldi, Elizabeth Keoshkerian, Yanran Zhao, Nicholas Brasher, Melanie R. Walker, Jens Bukh, Lisa Maher, Tom Gordo Tags: Research Article Source Type: research
EMC10 modulates hepatic ER stress and steatosis in an isoform specific manner
Endoplasmic reticulum (ER) membrane protein complex subunit 10 (EMC10) has been implicated in obesity. Here we investigated the roles of the two isoforms of EMC10, including a secreted isoform (scEMC10) and an ER membrane-bound isoform (mEMC10), in MASLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2024 Category: Gastroenterology Authors: Kuangyang Chen, Yahao Wang, Jia Yang, Nora Kl öting, Chuanfeng Liu, Jiarong Dai, Shuoshuo Jin, Lijiao Chen, Shan Liu, Yuzhao Liu, Yongzhuo Yu, Xiaoxia Liu, Qing Miao, Chong Wee Liew, Yangang Wang, Arne Dietrich, Matthias Blüher, Xuanchun Wang Tags: Research Article Source Type: research
Polyploidisation pleiotropically buffers ageing in hepatocytes
Polyploidy in hepatocytes has been proposed as a genetic mechanism to buffer against transcriptional dysregulation. Here, we aim to demonstrate the role of polyploidy in modulating gene regulatory networks in hepatocytes during ageing. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Kelvin Yin, Maren B üttner, Ioannis K. Deligiannis, Mateusz Strzelecki, Liwei Zhang, Carlos Talavera-López, Fabian Theis, Duncan T. Odom, Celia P. Martinez-Jimenez Tags: Research Article Source Type: research
Reply to: “Increase in HDV replication during steroid therapy – potential implications for testing and treatment strategies”
The case reported by Patmore et al.1 highlights the complexity of managing patients with chronic hepatitis D (CHD), particularly when the coexistence of liver damage co-factors may significantly impact the outcome of liver disease and jeopardize the patient’s treatment. Since 1983, a HDV-specific pattern of autoantibodies agai nst liver-kidney microsomal antigens has been described by indirect immunofluorescence in up to 13% of Italian patients with CHD.2 In the following years it was shown that, in addition to these autoantibodies targeting the uridine 5’-diphosphate-glucoronosyltransferases (UGT-1 family 1), severa...
Source: Journal of Hepatology - April 4, 2024 Category: Gastroenterology Authors: Gabriele Ricco, Maurizia R. Brunetto Tags: Letter to the Editor Source Type: research
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2
Functional cure (FC) for chronic hepatitis B (CHB) requires finite treatment. Two agents under investigation aimed at achieving FC are small interfering RNA JNJ-73763989 (JNJ-3989) and capsid assembly modulator JNJ-56136379 (JNJ-6379; bersacapavir). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2024 Category: Gastroenterology Authors: Kosh Agarwal, Maria Buti, Florian van B ömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, John Jezorwski, Daniel Muenz, Maria Beumont, Ronald Kalmeijer, Micha Tags: Research Article Source Type: research
Reply to: Increase in HDV replication during steroid therapy – potential implications for testing and treatment strategies
GR: acquisition of data; drafting of the manuscript. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2024 Category: Gastroenterology Authors: Gabriele Ricco, Maurizia R. Brunetto Tags: Letter to the Editor Source Type: research
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort
Steatotic liver disease (SLD), characterized by elevated liver fat content (LFC), is influenced by genetics and diet. However, whether diet has differential effect based on genetic risk is not well-characterized. We aimed to determine how genetic factors interact with diet to affect SLD in a large national biobank. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 3, 2024 Category: Gastroenterology Authors: Vincent L. Chen, Xiaomeng Du, Antonino Oliveri, Yanhua Chen, Annapurna Kuppa, Brian D. Halligan, Michael A. Province, Elizabeth K. Speliotes Tags: Research Article Source Type: research
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
There has been a lack of prospective data on treatment after immune checkpoint inhibitor (ICI) in hepatocellular carcinoma (HCC). We conducted a phase II multicentred study on cabozantinib in HCC after ICI treatment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 1, 2024 Category: Gastroenterology Authors: Stephen L. Chan, Baek-Yeol Ryoo, Frankie Mo, Landon L. Chan, Jaekyung Cheon, Leung Li, Kwan H. Wong, Nicole Yim, Hyeyeong Kim, Changhoon Yoo Tags: Research Article Source Type: research
Erratum to ‘JAK1 promotes HDV replication and is a potential target for antiviral therapy’ [J Hepatol 80 (2024) 220-231]
It has come to our attention that an error was introduced during the production of this manuscript. The labels of the legend in Fig. 6G have been reversed. The light blue bars should be labeled ‘WT’ and the white bars ‘MDA5-KO’. The correct figure is provided below. The authors and the editorial office apologize for any inconvenience caused. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 30, 2024 Category: Gastroenterology Authors: Margaux J. Heuschkel, Charlotte Bach, Laura Meiss-Heydmann, Emma Gerges, Emanuele Felli, Fabio Giannone, Patrick Pessaux, Catherine Schuster, Julie Lucifora, Thomas F. Baumert, Eloi R. Verrier Tags: Erratum Source Type: research
The MASLD criteria overlook a number of adolescent patients with severe steatosis
We read with a great interest the consensus statement on the proposed new fatty liver disease nomenclature to replace non-alcohol fatty liver disease (NAFLD) with metabolic dysfunction-associated steatotic liver disease (MASLD) and diagnostic criteria for diagnosing MASLD in children and adolescents 1. These criteria are similar (although not identical) to the diagnostic criteria of the metabolic dysfunction –associated fatty liver disease (MAFLD), which was the first definition to provide a set of positive diagnostic criteria that acknowledge that fatty liver is a continuum across the lifespan 2-4. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 29, 2024 Category: Gastroenterology Authors: Ziyan Pan, Mohammed Eslam, panel of collaborators Tags: Letter to the Editor Source Type: research
Reply to: Comments on “An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis”
We express our appreciation to our colleagues for their invaluable feedback1 –5 on our recent publication,6 which has garnered considerable interest. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Rom ée J.A.L.M. Snijders, Anna E.C. Stoelinga, Bart van Hoek, Joost P.H. Drenth Tags: Letter to the Editor Source Type: research
Reply to: “Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface”
We would like to thank our colleagues from Indianapolis for their interest in our work.1 We agree with Alkashash et al. that it is “at least the hope, that the biopsy might be able to differentiate between DI-ALH and cAIH”. Unfortunately, previous histological studies have not been able to distinguish between cAIH and DI-ALH. The authors fail to mention that a previous relatively large cohort of patients wi th cAIH and DI-ALH diagnosed at the Mayo Clinic did not reveal any histological difference in these entities except that none of the patients with DI-ALH had cirrhosis at baseline in comparison with 20% of those w...
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Einar S. Bj örnsson, M Isabel Lucena, Raul J. Andrade Tags: Letter to the Editor Source Type: research
Acute-on-chronic liver failure-steps for harmonization of the definition!
Acute-on-chronic liver failure (ACLF), usually precipitated by alcohol misuse or viral reactivation, is a rapid onset and usually reversible liver failure. There have been various definitions of ACLF proposed across the globe, including, Asian Pacific Association for the Study of Liver (APASL), Chinese Group on the Study of Severe Hepatitis B (COSSH), European Association for the Study of Liver-Consortium for Liver Failure (EASL-CLIF), Japanese definition, and North American Consortium for the Study of End-Stage Liver Disease (NACSELD) have been widely used. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Anand V. Kulkarni, Shiv Kumar Sarin Tags: Expert Opinion Source Type: research
Reply to the Letter to the Editor: Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface
We would like to thank our colleagues from Indianapolis for interest in our work.1 We agree with Alkashash et al. that it is “at least the hope, that the biopsy might be able to differentiate between DI-ALH and cAIH”. Unfortunately, previous histological studies have not been able to distinguish between cAIH and DI-ALH. The authors fail to mention that a previous relatively large cohort of patients with cAIH and DI-AL H diagnosed at the Mayo Clinic did not reveal any histological difference in these entities except that none of the DI-ALH patients had cirrhosis at baseline in comparison with 20% of the cAIH. (Source: J...
Source: Journal of Hepatology - March 28, 2024 Category: Gastroenterology Authors: Einar S. Bj örnsson, M Isabel Lucena, Raul J. Andrade Tags: Letter to the Editor Source Type: research
